The executive of a private health group has expressed disappointment that a planned inquiry into South Africa’s private healthcare market by the Competition Commission will not also umbrella the pharmaceutical sector. Netcare CEO Richard Friedland offered the remarks on Monday, noting that consumers pay “40 percent more” for drugs in South Africa. The Commission’s planned review of the healthcare market will bring private hospitals and medical schemes under a close watch but appears to let the pharmaceutical sector off the hook under the argument that pharmaceutical prices are already regulated. Further, Friedland said the allowance of parallel imports of drugs could help lower costs for consumers. Netcare is currently the nation’s third-largest private hospital group.
Featured News
The Hidden Security Risk Inside Your Company’s AI Tools
Mar 13, 2026 by
CPI
EU’s Largest Economies Push to Reduce Reliance on Foreign Payment Systems
Mar 12, 2026 by
CPI
Warren Presses Amazon for Answers on Pricing Practices for Government Buyers
Mar 12, 2026 by
CPI
EU Antitrust Chief Raises Concerns Over Big Tech Control of AI
Mar 12, 2026 by
CPI
Burson Adds Senior Advisor to Strengthen Competition Team
Mar 12, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Behavioral Economics
Feb 22, 2026 by
CPI
Behavioral Antitrust in 2026
Feb 22, 2026 by
Maurice Stucke
Behavioral Economics in Competition Policy: Going Beyond Inertia and Framing Effects
Feb 22, 2026 by
Annemieke Tuinstra & Richard May
Agreeing to Disagree in Antitrust
Feb 22, 2026 by
Jorge Padilla
Recognizing What’s Around the Corner: Merger Control, Capabilities, and the New Nature of Potential Competition
Feb 22, 2026 by
Magdalena Kuyterink & David J. Teece